Skip to main content
SpringerLink
Log in

A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Introduction

In recent years, several novel anticoagulants have been approved for the prevention of thromboembolic strokes as an alternative to warfarin in patients with atrial arrhythmias. Studies have evaluated these medications in patients undergoing radiofrequency ablation, yet no data exists to evaluate the bleeding risk in patients undergoing cryoballoon ablation procedures.

Methods

Patients that underwent either cryoballoon ablation alone or with additional radiofrequency ablation over the past 3 years were included in the study. Patients were stratified into one of three subsets based on type of anticoagulation (warfarin, dabigatran, or rivaroxaban). Bleeding complications during the first 48 h and first 2 weeks following the ablation were recorded. Major complications were defined as hemorrhage requiring blood products or need for vascular intervention. Minor complications included prolonged bleeding from catheter insertion site, development of ecchymosis, or hematoma formation. Intraprocedural activated clotting times (ACT) were assessed and compared.

Results

A total of 217 patients met inclusion criteria of which 87 (40.1 %) patients were on warfarin, 90 (41.5 %) patients on dabigatran, and 40 (18.4 %) patients on rivaroxaban. The overall bleeding complication rate was 12.0 %. All complications occurred within the first 48 h post-ablation. Nine (10.3 %) complications occurred in the warfarin subset, ten (11.1 %) in the rivaroxaban subset, and seven (17.5 %) in the dabigatran subset (p = 0.49). The warfarin and dabigatran subsets had higher average ACT levels (424.9 versus 406.5) compared to the rivaroxaban subset (393.4; p < 0.01). Subanalyses found no difference in bleeding complications based on procedure type.

Conclusion

Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Compared with radiofrequency ablation, cryoablation does not place patients at an increased bleeding risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Packer, D. L., Kowal, R. C., Wheelan, K. R., et al. (2013). Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. Journal of the American College of Cardiology, 61(16), 1713–1723.

    Article  PubMed  Google Scholar 

  2. Tse, H. F., Reek, S., Timmermans, C., et al. (2013). Pulmonary vein isolation using transvenous catheter cryoablation for treatment of atrial fibrillation without risk of pulmonary vein stenosis. Journal of the American College of Cardiology, 42(4), 752–758.

    Article  Google Scholar 

  3. Tayebjee, M. H., Hunter, R. J., Baker, V., et al. (2011). Pulmonary vein isolation with radiofrequency ablation followed by cryotherapy: a novel strategy to improve clinical outcomes following catheter ablation of paroxysmal atrial fibrillation. Europace, 13(9), 1250–1255.

    Article  PubMed  Google Scholar 

  4. Mansour, M., Forleo, G. B., Pappalardo, A., et al. (2010). Combined use of cryoballoon and focal open-irrigation radiofrequency ablation for treatment of persistent atrial fibrillation: results from a pilot study. Heart Rhythm, 7(4), 452–458.

    Article  PubMed  Google Scholar 

  5. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139–1151.

    Article  CAS  PubMed  Google Scholar 

  6. Patel, M. R., Mahaffey, K. W., Garg, J., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891.

    Article  CAS  PubMed  Google Scholar 

  7. Snipelisky, D., Kauffman, C., Prussak, K., Johns, G., Venkatachalam, K., & Kusumoto, F. (2012). A comparison of bleeding complications post-ablation between warfarin and dabigatran. Journal of Interventional Cardiac Electrophysiology, 35(1), 29–33.

    Article  PubMed  Google Scholar 

  8. Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal American College of Cardiology, 59(13), 1168–1174.

    Article  CAS  Google Scholar 

  9. Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23(3), 264–268.

    Article  PubMed  Google Scholar 

  10. Eitel, C., Koch, J., Sommer, P., et al. (2013). Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace, 15(11), 1587–1593.

    Article  PubMed  Google Scholar 

  11. Snipelisky, D., & Kusumoto, F. (2013). Current strategies to minimize the bleeding risk of warfarin. Journal of Blood Medicine, 4, 89–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Spinler, S. A., & Shafir, V. (2012). New oral anticoagulants for atrial fibrillation. Circulation, 126(1), 133–137.

    Article  PubMed  Google Scholar 

  13. Knight, B. P. (2012). Anticoagulation for atrial fibrillation: what is the optimal strategy? Journal of the American College of Cardiology, 59(13), 1175–1177.

    Article  PubMed  Google Scholar 

  14. Baglin, T. (2013). Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. British Journal of Haematology, 163(2), 160–167.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    David Snipelisky, Jordan C. Ray, Ryan Ung & Melissa Duart

  2. Department of Medicine, Division of Cardiovascular Diseases, Jacksonville, FL, 32224, USA

    Christine Kauffman & Fred Kusumoto

Authors
  1. David Snipelisky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan C. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan Ung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melissa Duart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Kauffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fred Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Snipelisky.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Snipelisky, D., Ray, J.C., Ung, R. et al. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol 41, 231–236 (2014). https://doi.org/10.1007/s10840-014-9948-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-014-9948-1

Keywords

Search

Navigation